CARD vs LABD

Key Takeaways

• CARD and LABD both target daily investment results of -300% of their respective underlying indices, making them high-risk, high-volatility instruments suited for short-term tactical use rather than long-term holding.
• CARD provides inverse leveraged exposure to the auto industry via an exchange-traded note (ETN) structure tracking the Prime Auto Industry Index, while LABD delivers the same daily target on the biotechnology sector through an exchange-traded fund (ETF) structure linked to the S&P Biotechnology Select Industry Index.
• The funds operate in entirely distinct sectors—automotive versus biotechnology—offering investors sector-specific bearish strategies rather than direct competition within the same market segment.
• Both products carry elevated expense ratios typical of leveraged and inverse vehicles, with LABD at approximately 1.07% net, reflecting costs associated with derivatives and daily rebalancing.
• Structural differences include CARD’s ETN format, which carries issuer credit risk, versus LABD’s ETF format that holds swaps, futures, and other derivatives to achieve its objective.
• Performance is driven primarily by the daily performance of their target indices, with compounding effects from daily resets amplifying volatility during periods of sector-specific news or broader market rotation.

Introduction

Investors seeking short-term inverse exposure to specific U.S. equity sectors may consider CARD and LABD as tactical tools within broader portfolios. These products do not compete directly for assets because they target different industries—automotive manufacturing and components for CARD, and biotechnology companies for LABD. Instead, they represent alternative strategies for expressing bearish views on distinct thematic areas that can be influenced by economic cycles, regulatory changes, or innovation trends. Their daily-reset leveraged structures make them sensitive to volatility and suitable primarily for experienced traders monitoring sector momentum.

Max Auto Industry -3X Inverse Leveraged ETN (CARD) Overview

CARD seeks daily investment results, before fees and expenses, of 300% of the inverse (opposite) of the daily performance of the Prime Auto Industry Index. The product is structured as an exchange-traded note (ETN) issued by MAX ETNs, exposing holders to the credit risk of the issuer in addition to market risk. It maintains a concentrated focus on approximately 23 constituents within the auto industry. As a leveraged inverse ETN, CARD relies on derivatives and does not hold underlying equities directly. The expense ratio is not publicly detailed in standard ETF formats due to its ETN structure but aligns with costs typical of complex leveraged products. Rebalancing occurs to maintain the -3x daily target, with monthly index reviews influencing constituent weights.

Direxion Daily S&P Biotech Bear 3X Shares (LABD) Overview

LABD seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund is an exchange-traded fund (ETF) that employs swaps, futures contracts, and short positions to achieve its objective. It is non-diversified and typically holds a modest number of derivative instruments rather than individual stocks. The net expense ratio stands at 1.07%. Daily rebalancing ensures alignment with the -3x target. The underlying index measures the performance of U.S. biotechnology companies classified under the Global Industry Classification Standard (GICS). This structure allows precise daily inverse exposure but introduces compounding effects over multi-day periods.

Industry and Thematic Backdrop

The automotive and biotechnology sectors operate under different macroeconomic and regulatory influences. Auto industry performance often correlates with consumer spending, interest rates, supply chain dynamics, and electric vehicle adoption trends. Biotechnology faces drivers such as clinical trial outcomes, Food and Drug Administration (FDA) approvals, healthcare policy shifts, and research and development spending. Both sectors can experience heightened volatility during earnings seasons or macroeconomic shifts, creating environments where inverse leveraged products may appeal to tactical investors. Capital flows into or out of these areas reflect broader risk sentiment and sector rotation patterns observed in recent market cycles.

Performance and Positioning Comparison

In recent weeks and months, both CARD and LABD have exhibited significant volatility consistent with their -3x daily targets, amplifying moves in their underlying indices. CARD’s positioning ties to auto sector rotations driven by economic data and production trends, while LABD responds to biotechnology-specific catalysts such as pipeline updates and funding environments. The relative performance differential stems from sector momentum rather than shared market factors. Over longer holding periods, daily compounding can cause returns to diverge substantially from the simple multiple of index performance, particularly in sideways or choppy markets. Investors typically position these vehicles for short horizons aligned with expected sector weakness.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Professional and retail investors seeking data-driven insights into instruments like CARD and LABD can leverage this platform for efficient market exploration.

Tickeron AI Verdict

Tickeron’s AI would currently assign a modest probabilistic preference to LABD over CARD based on its established ETF structure, which avoids issuer credit risk inherent in ETNs, combined with transparent derivatives-based implementation and a defined expense ratio. LABD’s focus on the biotechnology sector may also align with observable momentum characteristics in certain market cycles. Both products carry substantial structural risks due to leverage and daily reset mechanics, making any allocation subject to rigorous risk assessment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations